Evenity (Romosozumab) Mechanism of Action: Full Pathway

Sclerostin: The Brake Romosozumab Releases

Sclerostin is a 22-kDa glycoprotein encoded by the SOST gene on chromosome 17q21.31. Osteocytes, the most abundant bone cells embedded within mineralized matrix, produce nearly all circulating sclerostin. The protein acts as a paracrine brake on bone formation by binding to LRP5 and LRP6 co-receptors on the osteoblast surface, preventing Wnt ligands from initiating their downstream cascade 1.

Discovery Through Human Genetics

The clinical rationale for targeting sclerostin came from two rare genetic conditions. Sclerosteosis (loss-of-function SOST mutations) and van Buchem disease (a 52-kb deletion in the SOST regulatory region) both produce extremely dense, fracture-resistant bones 2. Heterozygous carriers of these mutations have above-average bone density without reported skeletal pathology. These human "experiments of nature" provided proof of concept that reducing sclerostin increases bone mass.

Sclerostin Regulation

Sclerostin expression rises with mechanical unloading (bed rest, spaceflight, immobilization) and increases with aging. Parathyroid hormone (PTH) suppresses SOST transcription, which partly explains how teriparatide stimulates bone formation 3. Mechanical loading through weight-bearing exercise also reduces sclerostin, linking physical activity to osteoblast stimulation through the same pathway that romosozumab pharmacologically exploits.

The Wnt/Beta-Catenin Pathway in Osteoblasts

Romosozumab's therapeutic effect depends on the canonical Wnt signaling cascade. This is the central molecular pathway controlling osteoblast differentiation, proliferation, and survival.

How the Pathway Works Without Drug

When sclerostin is absent or neutralized, Wnt ligands (Wnt3a, Wnt10b, and others) bind to the Frizzled/LRP5/6 receptor complex on osteoblast precursors. This binding recruits Dishevelled (Dvl) protein, which inhibits the "destruction complex" composed of Axin, APC, GSK-3-beta, and CK1-alpha. Without destruction complex activity, beta-catenin accumulates in the cytoplasm, translocates into the nucleus, and partners with TCF/LEF transcription factors to activate genes responsible for osteoblast commitment and mineralization 4.

What Sclerostin Normally Does to This Pathway

Sclerostin binds the first beta-propeller domain of LRP5/6, physically blocking Wnt ligand engagement. With the Wnt signal absent, the destruction complex phosphorylates beta-catenin, marking it for ubiquitin-mediated proteasomal degradation. The result: fewer active osteoblasts, less new bone matrix, and a net remodeling balance that favors resorption.

What Romosozumab Does

Romosozumab binds sclerostin with high affinity (Kd approximately 3 pM), sequestering it in the extracellular space. This "releases the brake," allowing endogenous Wnt ligands to engage LRP5/6 freely. Beta-catenin accumulates, osteoblast differentiation accelerates, and bone formation rate increases measurably within one month of the first dose 5.

The Dual-Effect Mechanism: Why Romosozumab Is Unique

Every other approved osteoporosis drug falls into one of two categories: antiresorptive (bisphosphonates, denosumab) or anabolic (teriparatide, abaloparatide). Romosozumab does both simultaneously. This is not marketing language. Bone turnover marker data confirm the dual effect clearly.

Anabolic Arm: Formation Markers Rise Fast

Serum P1NP (procollagen type I N-terminal propeptide), the standard bone formation marker, increases by approximately 145% above baseline within one month of the first romosozumab injection. This peak is transient. P1NP begins returning toward baseline by month 6 and reaches pre-treatment levels by month 9 to 12 6. The declining formation signal over the 12-month course explains why romosozumab is approved for only 12 doses and is not repeated.

Antiresorptive Arm: Resorption Markers Drop

Serum CTX (C-terminal telopeptide of type I collagen), the standard bone resorption marker, decreases by roughly 30 to 40% within the first month and remains suppressed throughout the 12-month treatment course. The mechanism behind this antiresorptive component is indirect. Wnt/beta-catenin activation in osteoblasts upregulates osteoprotegerin (OPG) expression. OPG is a decoy receptor for RANKL. More OPG means less free RANKL available to bind RANK on osteoclast precursors, which means fewer mature osteoclasts and less bone resorption 7.

The "Anabolic Window"

The concept of an "anabolic window" is clinically important for sequencing decisions. During months 1 through 6 of romosozumab, P1NP is elevated while CTX is suppressed. This produces the widest gap between formation and resorption rates, often called the "open modeling-based bone formation window." Histomorphometry from iliac crest biopsies in the FRAME trial confirmed increases in mineralizing surface (MS/BS), mineral apposition rate (MAR), and bone formation rate (BFR/BS) that were most pronounced in the first 6 months 8. After month 6, as the formation signal attenuates, romosozumab behaves increasingly like a pure antiresorptive. This trajectory shapes the clinical recommendation to transition patients to denosumab or a bisphosphonate immediately after the 12-month romosozumab course, preserving the BMD gained during the anabolic window.

Romosozumab vs. Other Bone-Active Pathways

Understanding romosozumab's mechanism is clearer when compared against other drug classes that work through entirely different signaling systems.

Teriparatide and Abaloparatide (PTH/PTHrP Analogs)

These drugs activate the PTH1 receptor on osteoblasts. Intermittent PTH receptor stimulation (once-daily injection) preferentially activates cAMP/PKA signaling and shifts bone remodeling toward formation. The antiresorptive effect is minimal. Both P1NP and CTX rise during treatment, meaning formation increases but resorption increases too, just less so. Romosozumab, by contrast, pushes formation up and resorption down at the same time 9.

Denosumab (Anti-RANKL)

Denosumab is a monoclonal antibody against RANKL itself. It reduces osteoclast formation and activity but has no direct anabolic effect on osteoblasts. Both P1NP and CTX drop during denosumab therapy. The two drugs target related but distinct nodes in bone biology. Romosozumab increases OPG (which blocks RANKL) as a secondary effect of Wnt activation. Denosumab blocks RANKL directly.

Bisphosphonates (Alendronate, Zoledronic Acid)

Bisphosphonates incorporate into hydroxyapatite and are released during osteoclast-mediated resorption, poisoning the mevalonate pathway inside osteoclasts and triggering apoptosis. They have no direct osteoblast stimulatory effect. In the ARCH trial, romosozumab followed by alendronate was compared against alendronate alone, directly testing whether leading with an anabolic agent that also suppresses resorption produces superior fracture reduction compared to antiresorptive-only therapy 10.

ARCH Trial: The Fracture Outcome Data

The ARCH trial (Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk) enrolled 4,093 postmenopausal women with osteoporosis and a prior fragility fracture. Patients received either romosozumab 210 mg monthly for 12 months followed by alendronate 70 mg weekly, or alendronate alone for the full study duration 10.

Vertebral Fracture Results

At 24 months (12 months of romosozumab then 12 months of alendronate vs. 24 months of alendronate), romosozumab-to-alendronate reduced new vertebral fracture risk by 48% compared to alendronate alone (6.2% vs. 11.9%, P<0.001). The number needed to treat (NNT) was approximately 18 over 24 months 10.

Non-Vertebral and Hip Fracture Results

Non-vertebral fractures were reduced by 19% (HR 0.81, 95% CI 0.66 to 0.99, P=0.04). Hip fracture risk was reduced by 38% (HR 0.62, 95% CI 0.42 to 0.92) 10.

BMD Changes

Lumbar spine BMD increased by 13.7% at 12 months with romosozumab vs. 5.0% with alendronate. Total hip BMD increased by 6.2% vs. 2.8%. These are the largest BMD increases reported for any single osteoporosis agent over 12 months in a phase 3 trial 10.

FRAME Trial: Placebo-Controlled Confirmation

The FRAME trial (Fracture Study in Postmenopausal Women with Osteoporosis) randomized 7,180 postmenopausal women with T-scores between -2.5 and -3.5 to romosozumab 210 mg monthly or placebo for 12 months, followed by denosumab 60 mg every 6 months in both groups 8.

Key Results

At 12 months, romosozumab reduced new vertebral fractures by 73% compared to placebo (0.5% vs. 1.8%, P<0.001). Lumbar spine BMD increased by 13.3% with romosozumab vs. 0.0% with placebo. After transition to denosumab, BMD gains were maintained and continued to increase modestly through month 24 8.

Histomorphometry Findings

Paired iliac crest biopsies at month 2 and month 12 showed that romosozumab increased modeling-based bone formation (formation on surfaces without prior resorption) at early time points. This is distinct from remodeling-based formation, which occurs on previously resorbed surfaces. The appearance of modeling-based formation is a histologic signature of Wnt pathway activation and separates romosozumab from antiresorptive agents that can only modulate remodeling 11.

Cardiovascular Safety Signal: The BRIDGE and ARCH Findings

The ARCH trial recorded a higher incidence of adjudicated serious cardiovascular events (cardiovascular death, myocardial infarction, stroke) with romosozumab versus alendronate during the first 12 months (2.5% vs. 1.9%). This imbalance led to the FDA black box warning 10. The BRIDGE trial, a male-only study, also showed numerically more cardiovascular events with romosozumab versus placebo, though the sample size (245 patients) limits interpretation 12.

Proposed Mechanisms for the CV Signal

The biological plausibility of cardiovascular risk from sclerostin inhibition remains debated. Sclerostin is expressed in the aortic valve and vascular smooth muscle. Some preclinical data suggest sclerostin may have a protective role against vascular calcification, meaning its inhibition could theoretically promote arterial calcium deposition 13. A Mendelian randomization study using SOST region variants found that genetically predicted lower sclerostin was associated with higher risk of cardiovascular events, supporting a causal link 14. The clinical significance for a 12-month treatment course versus lifelong genetic sclerostin reduction is uncertain, but the FDA label reflects a precautionary stance: romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year.

Sequencing Strategy After Romosozumab

The anabolic effect of romosozumab is self-limiting. Bone formation markers return to baseline by month 9 to 12, likely due to compensatory upregulation of other Wnt pathway inhibitors (DKK1, SFRP4) and feedback loops within osteocyte signaling 15.

Why Consolidation Therapy Is Mandatory

Stopping romosozumab without follow-on antiresorptive therapy leads to rapid BMD loss, similar to what occurs after denosumab discontinuation. In the FRAME extension, patients who transitioned from romosozumab to denosumab maintained 17.6% lumbar spine BMD gains at month 36, while those who switched from placebo to denosumab reached only 8.5% 8.

Recommended Sequences

The Endocrine Society 2020 guideline recommends romosozumab for 12 months followed by a potent antiresorptive (denosumab or zoledronic acid) in postmenopausal women at very high fracture risk 16. The American Association of Clinical Endocrinologists (AACE) 2020 guideline similarly positions romosozumab as first-line for patients with recent fracture or T-score <-3.0, with mandatory antiresorptive consolidation 17.

Teriparatide or abaloparatide after romosozumab is not recommended. Data from the STRUCTURE trial showed that switching from alendronate to teriparatide produced BMD gains, but switching in the opposite direction (anabolic to anabolic) has not been shown to produce additive benefit and may blunt the second agent's effect 18.

Pharmacokinetics and Dosing Rationale

Romosozumab follows nonlinear, target-mediated drug disposition (TMDD). At the approved dose of 210 mg subcutaneous monthly, steady-state Cmax averages 22.2 mcg/mL with a trough of approximately 7 mcg/mL. The effective half-life is 12.8 days, supporting the monthly dosing interval. Bioavailability after subcutaneous injection is approximately 81% 19.

Administration Specifics

Each 210 mg dose requires two separate 105 mg/1.17 mL prefilled syringes administered sequentially in the abdomen, thigh, or upper arm. Both injections should be given within the same clinic visit. No dose adjustment is required for renal impairment, though patients with creatinine clearance <30 mL/min are at higher risk of hypocalcemia and require calcium/vitamin D supplementation with monitoring 19.

Immunogenicity

Anti-romosozumab antibodies developed in 18.1% of patients in FRAME, but neutralizing antibodies were detected in only 0.7%. No clear relationship between antibody development and loss of efficacy or adverse events was identified 8.

Emerging Research: Beyond Postmenopausal Osteoporosis

Sclerostin inhibition is being studied in fracture healing, glucocorticoid-induced osteoporosis, and osteogenesis imperfecta. A phase 2 trial in children with osteogenesis imperfecta type I and IV (NCT03972228) is evaluating setrusumab, a different anti-sclerostin antibody. Romosozumab itself has phase 3 data in men (BRIDGE trial, N=245), showing 12.1% lumbar spine BMD gain at 12 months vs. 1.2% with placebo 12. The Endocrine Society guideline notes that romosozumab may be considered in men with osteoporosis at high fracture risk, though the cardiovascular safety data require careful patient selection 16.

Preclinical work in fracture repair models shows that sclerostin antibody treatment accelerates callus formation and increases mechanical strength of healing bone by 30 to 50% in rodent tibia fracture models 20. Whether this translates to clinical fracture healing benefit in humans is not yet established.

Patients with chronic kidney disease stage 4 to 5, who are typically excluded from bisphosphonate use, represent another population of interest. Sclerostin levels are elevated in CKD, and early data suggest that anti-sclerostin therapy may counteract renal osteodystrophy, but prospective safety data in this population are lacking.